Price $9.53 |
Market Cap
117M
|
Sector Health Care |
Div. Growth
-
|
|
P/E
-
|
P/B
2.86
|
P/S
2.55
|
Dividend %
-
|
|
P/CF
7.8
|
P/FCF
-
|
Op. Cash Flow
-2.3K
|
FCF
-0.3
|
|
Op. Margin
-10.30%
|
Net Margin
-30.60%
|
ROE
-37.00%
|
ROI
-29.60%
|
|
ROA
-30.10%
|
EPS Growth
-
|
Current Ratio
5.4
|
Debt/Equity
-
|
| Company | Price | P/E | Div. Yield | Market Cap ($Mil) | Rating |
|---|---|---|---|---|---|
| Enzon Pharmaceuticals Inc (ENZN) | $0.37 | - | - | 12.8M | Strong Buy |
| Pernix Therapeutics Holdings I (PTX) | $4.57 | - | - | 40.4M | Strong Buy |
| Perrigo Company PLC (PRGO) | $72.65 | - | 0.80% | 10.89B | Strong Buy |
| Valeant Pharmaceuticals Intl I (VRX) | $17.25 | - | - | 5.89B | Strong Buy |
| Navidea Biopharmaceuticals Inc (NAVB) | $0.48 | - | - | 83.4M | Strong Buy |
Please note that all recommendations are based on our model's results and do not represent our personal opinion. The stock Rating process is purely mechanical.
All analysis relies on publicly available financial information. Learn More
